跳至主要内容
临床试验/NCT05088902
NCT05088902Unknown不适用

Pilot Testing Manual For Validation Purposes Providing Clearance for COVID-19 Tested Individuals Using the TERA Bio Station T101

Tera Group1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2021年10月22日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
1,000
试验地点
1
主要终点
Clearing at least 80% of the healthy population

研究概览

简要总结

TERABio Ltd. has developed a rapid screening tool intended to determine if a tested individual is COVID-19-free (Negative to COVID-19).

详细描述

The goal of the pilot is to perform a localized validation to the TERA Bio Tests by TERA Bio Station(s). Success Criteria: Clearing at least 80% of the healthy population.

Pilot duration: approx. 6-10 work weeks long.

Research Population Requirements:

Male and Female, age ≥ 18 years old, whose COVID-19 virus infection status is known and verified for at least the last 24 hours (prior to the TERA.Bio test).

The study will include a minimum of 300 tested Positive individuals and a minimum of 700 Negative individuals, tested during the 24 hours prior to the TERA.Bio test.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years old (under 18 years old - only if it is allowed under local regulations and with legal guardian's approval and consent if needed.
  • COVID-19 virus infection status is known and verified 24 hours prior to a TERA.Bio test by RT-PCR and if required, a repeated PCR test based on symptomatic status and or / the CT value of the tested individual.
  • Signed Informed consent form.

排除标准

  • Discrepancies to inclusion criteria
  • Individuals under general anaesthesia
  • Individuals lacking the capability to personally sign the consent form.
  • Individuals lacking the capability to exhale breath.

结局指标

主要结局

Clearing at least 80% of the healthy population

时间窗: 7 Weeks (Estimated)

TERABio Ltd. has developed a rapid screening tool intended to determine if a tested individual is COVID-19-free (Negative to COVID-19). The goal of the pilot is to perform a localized validation to the TERA Bio Tests by TERA Bio Station(s)- Success Criteria -Clearing at least 80% of the healthy population.

次要结局

未报告次要终点

研究者

发起方
Tera Group
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Validation of TERA Bio Station T101 of COVID-19... | 临床试验